Pfizer

R&D round-up: Non-opioid painkiller space heats up
R&D round-up: Non-opioid painkiller space heats up
Pharmaforum
painkillers
opioids
non-opioid pain treatments
Merck
Kings College London
Pfizer
Eli Lilly
tanezumab
Xeljanz
Flag link:
Using Pfizer’s smoking-cessation treatment Chantix to control neurons for drug research
Using Pfizer’s smoking-cessation treatment Chantix to control neurons for drug research
Fierce Biotech
Pfizer
Chantix
Flag link:
Ian Read bags $19.5 million, taking a big pay cut for his swan song as Pfizer CEO and leaving the pharma giant at a crossroads
Ian Read bags $19.5 million, taking a big pay cut for his swan song as Pfizer CEO and leaving the pharma giant at a crossroads
Endpoints
Pfizer
Pharma CEOs
executive pay
Ian Read
Albert Bourla
Flag link:
Pfizer gets FDA approval for oncology biosimilar Trazimera
Pfizer gets FDA approval for oncology biosimilar Trazimera
Pharmaceutical Business Review
Pfizer
FDA
Trazimera
Genentech
biosimilars
Herceptin
Flag link:
Pfizer settles Oregon probe over false advertising
Pfizer settles Oregon probe over false advertising
Seattle Times, WA
Pfizer
Oregon
copay coupons
Flag link:
AbbVie and Pfizer return to the top of pharma's TV spending list for February
AbbVie and Pfizer return to the top of pharma's TV spending list for February
Fierce Pharma
AbbVie
Humira
Pfizer
Xeljanz
television ads
DTC ads
Flag link:
Bayer files prostate cancer drug darolutamide in Japan
Bayer files prostate cancer drug darolutamide in Japan
Pharmaforum
Bayer
prostate cancer
darolutamide
Japan
JNJ
Pfizer
Astellas
Flag link:
Top 10 drugs losing exclusivity in 2019
Top 10 drugs losing exclusivity in 2019
Fierce Pharma
market exclusivity
patents
Rituxan
Lyrica
Herceptin
Avastin
Epclusa
Harvoni
Pfizer
Roche
Gilead Sciences
Amgen
GSK
Allergan
Individor
Flag link:
Teva launches generic for Pfizer’s Flector pain patch
Teva launches generic for Pfizer’s Flector pain patch
Drug Delivery Business News
Teva Pharmaceutical
generics
Pfizer
Flector
pain patches
Flag link:
AbbVie, Akcea benefit from latest CHMP recommendations
AbbVie, Akcea benefit from latest CHMP recommendations
Biopharma Dive
Europe
CHMP
AbbVie
Akcea
Biomarin
Sanofi
Pfizer
drug approvals
Flag link:
Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz
Pfizer’s blockbuster safety issue jumps the Atlantic as EMA launches its own review of Xeljanz
Endpoints
Pfizer
Europe
JAK inhibitors
Xeljanz
Flag link:
Pfizer unit Meridian under civil investigation by U.S. Attorney
Pfizer unit Meridian under civil investigation by U.S. Attorney
Yahoo/Reuters
Pfizer
Meridian Medical Technologies
drug manufacturing
Epi Pens
Flag link:
Does Pfizer's Xeljanz share its CV safety questions with burgeoning JAK class?
Does Pfizer's Xeljanz share its CV safety questions with burgeoning JAK class?
Fierce Pharma
Pfizer
Xeljanz
JAK inhibitors
Flag link:
The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress
The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress
Stat
drug pricing
US Congress
Donald Trump
Richard Gonzalez
AbbVie
Ken Frazier
Merck
JNJ
Jennifer Taubert
Olivier Brandicourt
Sanofi
Pascal Soriot
AstraZeneca
Giovanni Caforio
Bristol-Myers Squibb
Albert Bourla
Pfizer
Flag link:
Pfizer CNS spinout Cerevel brings on new CMO to launch phase 3 work in Parkinson’s disease
Pfizer CNS spinout Cerevel brings on new CMO to launch phase 3 work in Parkinson’s disease
Fierce Biotech
Cerevel Therapeutics
Pfizer
Otsuka
CMOs
Parkinson's Disease
epilepsy
Flag link:
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Pfizer, Merck, J&J well-positioned for M&A and Biogen and BioMarin are prime targets: report
Fierce Pharma
M&A
oncology
neurology
Rare Diseases
Pfizer
Merck
JNJ
Biogen
Biomarin
Flag link:
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
CP Wire
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
Flag link:
Pfizer drops higher dose treatment arm in Xeljanz post-marketing study due to safety issues
Pfizer
Xeljanz
post-marketing studies
FDA
rheumatoid arthritis
ulcerative colitis
Flag link:
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Pfizer's Forgotten Cancer Pill Is About to Become Its Next Blockbuster
Motley Fool
Pfizer
Inlyta
kidney cancer
Merck
Keytruda
Flag link:
Higher dose of Pfizer-Lilly drug helps reduce back pain in study
Higher dose of Pfizer-Lilly drug helps reduce back pain in study
Yahoo/Reuters
Pfizer
Eli Lilly
chronic low back pain
low back pain
clinical trials
tanezumab
opioid alternatives
Flag link:

Pages